Engage with the Class Action for Applied Therapeutics Investor Recovery
The Gross Law Firm extends a crucial notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT). If you have invested in APLT, it is essential to be aware of the ongoing class action lawsuit that aims to seek recovery for those who may have incurred losses.
Why You Should Consider Joining This Class Action
If you purchased shares of Applied Therapeutics during the specified period, you are encouraged to reach out to the firm. Participating as a lead plaintiff is not a necessity; however, joining the class action could be beneficial for potentially recovering your investments.
Understanding the Class Period
The class action encompasses those who bought shares between January 3, 2024, and December 2, 2024. During this time, significant events impacted the stock's performance, raising concerns about the company's operations and practices.
Allegations Against Applied Therapeutics
On November 27, 2024, Applied Therapeutics released a statement revealing that the FDA had issued a Complete Response Letter regarding its new drug application for govorestat, the company's primary drug candidate. This letter indicated that the FDA had completed its review but could not approve the application due to clinical application deficiencies. Following this announcement, the company's stock price experienced a sharp decline. From a closing price of $10.21 on November 26, 2024, shares dropped to $8.57 the following day and plummeted further over the next few days, falling to as low as $1.75 by December 2, 2024—a staggering decrease of over 80%.
Impact of Recent Developments
After market hours on December 2, 2024, Applied Therapeutics disclosed that it received a warning letter from the FDA concerning the clinical trial issues underlying the Complete Response Letter. This news only intensified the worries of investors and contributed to further declines in the stock price. Investors should be aware of the serious implications of these revelations on the financial standing of Applied Therapeutics.
Critical Deadlines for Shareholders
It is crucial for shareholders to act swiftly. The deadline for registering in this class action is on February 18, 2025. Delaying registration may erase your chance for potential recovery. If you’re eligible, ensure your information is registered promptly.
Next Steps to Take
Upon registering as a shareholder for this class action, you will have access to monitoring tools that keep you updated throughout the proceedings. Participants do not incur any costs in joining this initiative, which emphasizes the commitment of the Gross Law Firm to assist investors without imposing financial burdens.
Why Choose The Gross Law Firm?
The Gross Law Firm stands as a nationally recognized entity committed to safeguarding the rights of investors subjected to deception and unethical business practices. The firm’s mission is to pursue recovery on behalf of investors who have faced losses due to misleading statements or critical omissions from the company. The Gross Law Firm upholds a strong position for accountability and good corporate conduct.
Contact Information
If you wish to learn more or have inquiries regarding the class action, reach out to The Gross Law Firm:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the purpose of the class action lawsuit against Applied Therapeutics?
The class action lawsuit aims to seek recovery for shareholders who incurred losses due to significant stock price declines following misleading information from the company.
How does one join the class action?
Shareholders should register their information before the deadline of February 18, 2025, to be part of the class action.
What are some of the allegations made against Applied Therapeutics?
The allegations include the company’s failure to secure FDA approval for a crucial drug due to deficiencies in its application, which led to a drastic fall in stock price.
Is there a cost to participate in the class action?
No, participating in the action is free of charge; shareholders can join without incurring any expenses.
Where can I find more updates about my case?
Once registered, you’ll receive updates through a portfolio monitoring system that provides status changes throughout the case lifecycle.
